values ranging from 0.06 to 30.05 μM. Complex 3 proved to be as potent as the reference drug benznidazole whereas complexes 4–6 were more potent than benznidazole as antiparasitic agents. The antimony(III) (4, EC50 = 0.33 μM) and bismuth(III) (6, EC50 = 0.06 μM) complexes presented the highest activities against the extracellular parasites. As expected, complexes 4 and 6 also exhibited the highest anti-T
在本工作中,获得了
8-羟基喹啉衍生的hydr,即2-甲酰基-
8-羟基喹啉-4-硝基
咪唑hydr(H2Q4NO 2 Im)(H 2 La,1)和2-甲酰基-
8-羟基喹啉-4-
硝基苯hydr ( H2Q4NO 2 Ph·H 2 O)(H 2 Lb,2)及其
锑(III)[Sb(L)Cl 2 ](3,4)和
铋(III)[Bi(L)Cl 2 ] (5、6)复合体。首先在未感染的人和小鼠细胞中确定化合物的细胞毒性浓度范围。此外,评估了它们对南美锥虫病致病性克鲁氏锥虫的抗寄生虫活性。当H 2 Lb(2)失活时,H 2 La(1)和配合物3-6抑制了克鲁氏锥虫的拟鞭毛虫的
EC 50值在0.06至30.05μM之间。复合物3被证明与参考药物苯硝唑一样有效,而复合物4–6比苯硝唑作为抗寄生虫药更有效。
锑(III)(4,
EC 50 = 0.33μM)和
铋(III)(6,
EC 50 = 0.06μM)复合物对细胞